Immunosuppressive therapy together with hematopoietic stem cell transplantation is used in the management of acquired severe aplastic anemia. However, despite significant improvement in these two treatment modalities, graft failure and graft-versus-host disease still remains the major challenge that needs to be addressed.Mesenchymal stem cells (MSCs) are adult multipotent cells capable of multipotential differentiation that possess immunosuppressive properties and are in use in the clinical setting to treat graft-versus-host disease. Because of their fundamental function in maintaining HSC self-renewal and regulating hematopoiesis, MSC have also been used to facilitate donor HSC engraftment. In this study we report our experience with a severe aplastic anemia patient who failed to respond to three allogeneic hematopoietic stem cell transplantation, but after the co-administration of MSC fully recovered a hematopoietic system within 4 weeks and became transfusion independent. To investigate the role of MSC during the transplant and establish their fate after the hematopoietic recovery, we characterized the MSC isolated from the patient before (pre-transplant) and after (post transplant) his successful transplant and compared them with the normal MSC.
Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation
TISATO, Veronica;
2010
Abstract
Immunosuppressive therapy together with hematopoietic stem cell transplantation is used in the management of acquired severe aplastic anemia. However, despite significant improvement in these two treatment modalities, graft failure and graft-versus-host disease still remains the major challenge that needs to be addressed.Mesenchymal stem cells (MSCs) are adult multipotent cells capable of multipotential differentiation that possess immunosuppressive properties and are in use in the clinical setting to treat graft-versus-host disease. Because of their fundamental function in maintaining HSC self-renewal and regulating hematopoiesis, MSC have also been used to facilitate donor HSC engraftment. In this study we report our experience with a severe aplastic anemia patient who failed to respond to three allogeneic hematopoietic stem cell transplantation, but after the co-administration of MSC fully recovered a hematopoietic system within 4 weeks and became transfusion independent. To investigate the role of MSC during the transplant and establish their fate after the hematopoietic recovery, we characterized the MSC isolated from the patient before (pre-transplant) and after (post transplant) his successful transplant and compared them with the normal MSC.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
